ETECTION of HbO 2 desaturation by using NIRS of the skull was first reported by Jobsis. 11 After 20 years, this technology was developed for clinical application. 8, 28 We compared two NIRS instruments that are commercially available for the measurement of tissue HbO 2 saturation. These instruments are the INVOS3100A device (Somanetics Corp., Troy, MI), approved by the United States Food and Drug Administration, and the investigational NIRO500 device (Hamamatsu Photonics Corp., Hamamatsu, Japan). Both instruments differ substantially in design. Our aim was to examine simultaneously the responses of these two instruments to isocapnic hypoxia and hyperoxic hypercapnia in healthy volunteers.
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Abbreviations used in this paper: CBF = cerebral blood flow; EKG = electrocardiographic; ETCO 2 = end-tidal CO 2 ; dHb = deoxyhemoglobin; HbO 2 = oxyhemoglobin; HR = heart rate; MABP = mean arterial blood pressure; NIRS = near-infrared spectroscopy; rSO 2 = regional (Hb) O 2 saturation; SaO 2 = arterial (Hb) O 2 saturation; tHb = total Hb. The experimental paradigm consisted of five steps. 1) For the first 5 minutes, the volunteer inhaled room air and stable baseline measurements were obtained. 2) At the end of this 5-minute period, unbeknownst to the volunteer, the inspired gas was switched to the first test gas (7% CO 2 in O 2 or 10% O 2 /5% CO 2 /85% N 2 ). The order in which the test gases were administered was randomized. While monitoring continued the volunteer breathed the gas for 5 minutes or until voluntarily disconnecting from the mouthpiece.
3) The inspired gas was switched back to room air. During 5 minutes of breathing the normal control gas mixture, stable recordings were again obtained. 4) The inspired gas was switched to the second test gas for 5 minutes. 5) Inhalation of room air resumed.
Acquisition of data from the NIRO500 was accomplished via a serial port into a 486 computer running appropriate software (Software Wedge program; Tal, Inc., Philadelphia, PA). The data from the INVOS3100A were collected on a 3.5-in computer diskette. Statistical analysis of the data was performed using analysis of variance for repeated measures and post hoc analysis was performed using Tukey's multiple comparison test with sta-tistical significance assigned to a maximum probability value of 0.05.
In Vivo NIRS
This technique exploits the fact that light in the nearinfrared region (600-1000 nm) penetrates tissue to a depth of 8 to 10 cm. Because the adult head is thicker than 8 to 10 cm, NIRS is used in the reflectance mode, that is, light is passed into and received on the same side of the head. The NIRS technique relies on the fact that Hb is a strong absorber of near-infrared light and that the amount of absorption varies with the degree of Hb oxygenation. The light absorbed by a compound is proportional to the molar absorption coefficient times the log of the ratio of transmitted light to incident light (log 10 I/I o ) and the pathlength (Beer Lambert law). In NIRS, the problem for quantitation is the measurement of pathlength. At present, there is no commercially available instrument that continuously measures pathlength, thus allowing for measurement of absolute Hb concentration in micromolar concentrations.
The necessity of knowing the pathlength was resolved for the INVOS3100A instrument by taking the ratio of the HbO 2 absorption signal to absorption at the isobestic point, allowing calculation of the percentage of HbO 2 . 8, 15 Normal adult rSO 2 values range from 65 to 75%. The INVOS3100A device uses two detectors positioned 30 and 40 mm from the light-emitting diode. The subtraction of the near from the far signal allows the subtraction of skin and bone, which is effective. 9 An important aspect of this instrument is that the percentage of HbO 2 is an absolute value that correlates with cerebral venous blood. 21 The NIRO500 device uses four wavelengths with laser diodes to separate the signals of three chromophores: HbO 2 , dHb, and cytochrome oxidase. Total Hb is the calculated sum of HbO 2 and dHb. Changes in these measurements are recorded in micromolar concentrations, but are referenced to an arbitrary baseline of zero.
Results

Figures 1 and 2 illustrate changes observed in one vol-
unteer. Using the INVOS3100A device ( Fig. 1) , we observed that a 7% decrease in rSO 2 occurred during hypox- ia and an 8% increase during hypercapnia. During hypoxia, arterial HbO 2 decreased from 96 to 84% saturation. Using the NIRO500 device (Fig. 2) , we found that hypoxia decreased HbO 2 by 10 M after two exposures, whereas hypercapnia induced a 15-M increase in HbO 2 .
Physiological variables of HR, MABP, ETCO 2 , and SaO 2 were continuously monitored, breath by breath, in each volunteer (Table 1) . Intersubject differences were observed. During hypercapnia, the HR was higher in two volunteers; MABP was higher in one volunteer; and SaO 2 was lower in one compared with the other volunteers. During hypoxia, the HR was lower in one volunteer and the ETCO 2 was lower in another. There were no EKG abnormalities or adverse events.
During hypercapnia, ETCO 2 increased from 42 Ϯ 2 to 56 Ϯ 3 mm Hg (p Ͻ 0.01). As shown in Table 2 , SaO 2 ranged between 97% (normocapnia) and 99% (hypercapnia). Hypoxia decreased SaO 2 to 87 Ϯ 3% from the normoxic value of 98 Ϯ 1% (p Ͻ 0.01).
Hypercapnia induced significant (p Ͻ 0.01) changes in regional cerebral Hb oxygenation, which were detected by both the NIRO500 and INVOS3100A instruments ( Table  3 ). The NIRO500 device detected an increase in HbO 2 of 11.6 Ϯ 3 M (p Ͻ 0.0008) or 0.793 M/mm Hg CO 2 (mean Ϯ standard deviation). The INVOS3100A device recorded an increase in HbO 2 saturation of 7.3 Ϯ 0.2% (p Ͻ 0.005) or 0.766 Ϯ 0.305%/mm Hg ETCO 2 , similar to that observed using the NIRO500 device. Isocapnic hypoxia decreased HbO 2 by 9.7 Ϯ 6.3 M (p Ͻ 0.005), or a Ϫ0.88 Ϯ 0.553-M change per percentage of SaO 2 with the NIRO500; whereas the INVOS3100A device recorded an average rSO 2 decrease of 5.1 Ϯ 1.2% (p Ͻ 0.0008) or Ϫ0.641 Ϯ 0.101% rSO 2 per percentage of SaO 2 change.
Discussion
The responses we observed using the NIRO500 instrument were generally similar to but somewhat greater than those observed using the INVOS3100A device. This may be due to the fact that, unlike the INVOS3100A, the NIRO500 makes no correction for skin and bone contamination. The subtraction technique used with the INVOS-3100A and the more recent models, the 4100 and 5100, effectively removes contamination by skin and bone. 9 These findings are consistent with our observations during carotid endarterectomy in an earlier study in which the INVOS3100A was four times less sensitive to extracranial contamination than the NIRO500. 2 Changes we observed using the INVOS3100A and NIRO500 devices during hypercapnia were almost twofold greater than those reported by Grubhofer, et al., 5 who compared the NIRO500 and INVOS3100 instruments during hyperventilation. A four-point decrease in rSO 2 occurred with hyperventilation sufficient to decrease ETCO 2 by 15 mm Hg. The difference in response is probably explained by the well-known difference in cerebrovascular reactivity at CO 2 levels above and below normal. The increase in CBF is much greater when the CO 2 level is above normal than when it is below normal. 6 Other investigators have also shown that NIRS reliably detects changes in cerebral oxygenation during both hypercapnia 25, 27 and hypocapnia 7 and during hypoxia. 5 This technology has shown its usefulness in a variety of clinical applications, including the detection of cerebral ischemia during carotid endarterectomy, 2,22 regional low-flow perfusion during cardiopulmonary bypass in neonates, 20 endoscopic thoracic sympathectomy, 24 and cardiopulmonary bypass. 3, 13 Cerebral oximetry is valuable in the intensive care unit, where it is used to monitor for cerebral vasospasm after subarachnoid hemorrhage 1, 12 and to optimize arterial blood pressure, ETCO 2 , or hematocrit (unpublished data).
It must be recognized that cerebral oximetry performed using NIRS does not measure CBF, although in the metabolizing brain, oxygenation and desaturation will occur when CBF increases and decreases, respectively. The fact that it does not measure CBF becomes apparent in the infarcted brain or in cases of brain death in which there is no tissue perfusion. 19 It is not surprising, therefore, that early reports of findings of NIRS and, in particular, data obtained using the INVOS3100A device, did not correlate with the absence of cerebral perfusion. Based on this the authors implied that NIRS does not work. 4, 16, 23 It is also unreasonable to expect that cerebral oximetry performed using NIRS would correlate with internal jugular bulb oximetry in head-injured patients. 14, 26 Head injury itself is very heterogeneous and therefore, jugular bulb O 2 saturation cannot be a standard for comparison with cerebral oximetry performed using NIRS. 17, 18 Although the concept of microvascular shunt placement and the notion that capillary PO 2 is lower than venous PO 2 in areas with shunts are not new, verification of the concept was provided by Ince and Sinaasappel, 10 who used palladium phosphorescence to measure capillary PO 2 and indicated that the PO 2 gap was evidence of shunting in sepsis and shock. 
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